InVivo Therapeutics to Present at 55th International Spinal Cord Society Annual Scientific Meeting
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President of Clinical Operations
& Project Management, is scheduled to present at the 55th International Spinal Cord Society (ISCoS) Annual
Scientific Meeting to be held September 14-16, 2016 in Vienna, Austria. Ms. Neff was invited to present along with several other
leaders in the field of spinal cord injury clinical research on September 14 during the symposium titled “Clinical Trials Update
for 2016.” The symposium, organized by the Spinal Cord Outcomes Partnership Endeavor (SCOPE), is intended to provide an update on
current clinical research to foster communication between researchers and clinicians on advancements and challenges in clinical
research.
“I am excited to share our encouraging progress to date and partake in the discussion on the challenges of conducting clinical
studies in the spinal cord injury patient population,” Ms. Neff said.
For more information regarding the meeting, visit: https://www.iscosmeetings.org/
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the
decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity
formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal
Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated
in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord
injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered
in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160907005101/en/